Clinical trial NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Official title: E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Smoldering Myeloma
Smoldering Multiple Myeloma
Keywords: Smoldering myeloma
Smoldering Multiple Myeloma
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: Bristol-Myers Squibb
name: Celgene
name: Blood Cancer Research Partnership
name: Multiple Myeloma Research Consortium
name: The Leukemia and Lymphoma Society
First posted: 2014-10-31
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.

Detailed description: This research study is a Phase II clinical trial, which tests the effectiveness of the investigational drugs elotuzumab, lenalidomide and dexamethasone in smoldering multiple myeloma. Recent research studies have shown that early treatment of smoldering multiple myeloma may delay or prevent the progression to active multiple myeloma. The purpose of this research study is to learn whether the combination of elotuzumab, lenalidomide and dexamethasone works in treating smoldering multiple myeloma.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Must have smoldering myeloma with high risk markers based on the Mayo OR the Spanish criteria as described below
* \>10% plasma cells in the bone marrow and any one or more of the following:

  * Serum M protein of 3 g/dL or greater
  * IgA SMM
  * Immunoparesis with reduction of two uninvolved immunoglobulin isotypes
  * Serum involved/uninvolved free light chain ratio ≥8 (but less than 100)
  * Progressive increase in M protein level (Evolving type of SMM)†
  * Bone marrow clonal plasma cells 50-60%
  * Abnormal plasma cell immunophenotype (≥95% of bone marrow plasma cells are clonal) and reduction of one or more uninvolved immunoglobulin isotypes
  * t (4;14) or del 17p or 1q gain
  * Increased circulating plasma cells
  * MRI with diffuse abnormalities or 1 focal lesion
  * PET-CT with focal lesion with increased uptake without underlying osteolytic bone destruction † Increase in serum monoclonal protein by ≥25% on two successive evaluations within a 6 month period
* No evidence of CRAB (see below for details) criteria or new criteria of active multiple myeloma which including the following:

  * Increased calcium levels (corrected serum calcium \>0.25 mmol/dL above the upper limit of normal or \>.275 mmol/dL)
  * Renal insufficiency (attributable to myeloma)
  * Anemia (Hb 2g/dL below the lower limit of normal or \<10g/dL)
  * Bone lesions (lytic lesions or generalized osteoporosis with compression fractures)
  * No evidence of the following new criteria for active MM including the following: Bone marrow plasma cells ≥ 60%, Serum involved/uninvolved FLC ratio ≥100, and MRI with more than one focal lesion

    * Participants with CRAB criteria that are attributable to conditions other than the disease under study may be eligible
* ECOG Performance Status (PS) 0, 1, or 2 (Appendix A)
* The following laboratory values obtained ≤ 14 days prior to registration:

  * ANC ≥1000/µL
  * PLT ≥ 50,000/µL
  * Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.)
  * AST ≤ 3 x institutional upper limit of normal (ULN)
  * ALT ≤ 3 x institutional upper limit of normal (ULN)
  * Estimated creatinine clearance ≥ 60mL/min or a creatinine ≤ 2.2 mg/dL
* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
* Females of childbearing potential\* must have a negative serum or urine pregnancy test
* Men must agree to use a latex condom during sexual contact with a female of childbearing potential even if they have had a successful vasectomy
* Ability to understand and the willingness to sign a written informed consent.
* Exclusion Criteria:
* Symptomatic Multiple Myeloma or any evidence of CRAB criteria including the new criteria for overt myeloma. Any prior therapy for active Myeloma should also be excluded. Prior therapy for smoldering myeloma is not an exclusion criteria. Bisphosphonates are not excluded
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational. Prior therapy with bisphosphonate is allowed. Prior radiation therapy to a solitary plasmacytoma is allowed. Prior clinical trials for smoldering MM or MGUS are allowed as long as the last therapy was at least 2 months prior and there was no improvement in M spike
* Serious medical or psychiatric illness likely to interfere with participation in this clinical study
* Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy
* Uncontrolled intercurrent illness
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to elotuzumab or lenalidomide
* Known seropositive for or active viral infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus. Patients who are seropositive because of hepatitis B virus vaccine are eligible

Primary outcomes:
measure: Percent of Patients Who Are Progression Free at 2 Years
timeFrame: 2 Years
Secondary outcomes:
measure: Objective Response Percent
timeFrame: 2 Years from start of treatment
measure: Time to Progression
timeFrame: From start of treatment up to +/- 60 months
measure: Overall Survival
timeFrame: From start of treatment up to +/- 60 months
Other outcomes:
Locations:
city: Denver
country: United States
facility: Colorado Blood Cancer Institute
state: Colorado
city: Hartford
country: United States
facility: St Francis Hospital and Medical Center
state: Connecticut
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Brewer
country: United States
facility: Eastern Maine Medical Center
state: Maine
city: Baltimore
country: United States
facility: University of Maryland
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Detroit
country: United States
facility: Barbara Ann Karmanos Cancer Institute
state: Michigan
city: Charlotte
country: United States
facility: Levine Cancer Institute
state: North Carolina
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Irene Ghobrial, MD
role: PRINCIPAL_INVESTIGATOR
References: